Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 2;20(1):127.
doi: 10.1186/s12943-021-01429-0.

Tetraspanin8 expression predicts an increased metastatic risk and is associated with cancer-related death in human cutaneous melanoma

Odile Berthier-Vergnes  1 , Laetitia Barbollat-Boutrand #  2 , Roxane M Pommier #  2 , Arnaud de la Fouchardière  2   3 , Patrick Combemale  3 , Maxime Grimont  2 , Noémie Lopez-Ramirez  2 , Julie Caramel  2 , Stéphane Dalle  2 , Jean-Luc Perrot  4 , Caroline Gaudy-Marqueste  5 , Nicolas Macagno  5 , Sandrine Mansard  6 , Fanny Bouquet  7 , Ingrid Masse  8   9
Affiliations

Tetraspanin8 expression predicts an increased metastatic risk and is associated with cancer-related death in human cutaneous melanoma

Odile Berthier-Vergnes et al. Mol Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest disclosure statement: FB is a member of Institut Roche, an affiliate of Hoffman-La Roche that has funded this study. The other authors report no conflicts of interest in this work.

Figures

Fig. 1
Fig. 1
TCGA analysis shows that TSPAN8 mRNA expression correlates with metastases dissemination and reduced disease free survival of patients harboring cutaneous melanomas. a TSPAN8 mRNA expression distribution across TCGA melanoma cohort: Gaussian finite mixture models (mclust R package) was applied and identified two Gaussian subdistribution in melanoma (TCGA RSEM log2), one relying to absent/low TSPAN8 expression tumors (black lines) and the other to high TSPAN8 expression tumors (red lines). Each bar on the x axis corresponds to one tumor. b Tumor number according to Clark’s level versus TSPAN8 mRNA expression: for each level of Clark classification, the number of tumors expressing absent/low or high TSPAN8 mRNA as well as the percentage of TSPAN8+ tumor are presented for all TCGA samples (n = 414; left panel) or for primary tumors only (n = 100; right panel). c, Sample distribution according to their Breslow thickness for tumors with absent/low or high TSPAN8 expression levels, in the totality of TCGA samples (n = 414; left panel) or for primary tumors only (n = 100; right panel). Wilcoxon rank-sum tests. d Tumor number according to the type of samples (primary tumor, regional cutaneous tissue, regional lymph node or distant metastasis): for each category, the number of tumors expressing absent/low or high TSPAN8 mRNA as well as the percentage of TSPAN8+ tumor is presented for all TCGA samples (n = 414). Fisher’s exact test. e, Number and percentage of samples expressing TSPAN8 mRNA at high level versus low (or absent) level according to the location: in primary tumors or in metastatic samples (n = 414). Fisher’s exact test
Fig. 2
Fig. 2
Tspan8 protein expression can be immunoscored in primary melanomas and correlates with a higher propensity to give rise to distant metastases, an increased risk of death and the presence of a BRAFV600E mutation. a Tspan8 expression detected by immunochemistry in different melanoma samples from immunoscore 1 to 4 (4 first pictures). b, Repartition of primary melanomas according to the Breslow Index (inferior to 1 mm, between 1 and 3 mm, superior to 3 mm), the patient status 5 years after diagnosis (dead or alive) and Tspan8 protein expression (positive or negative): for each category, the percentage of Tspan8+ tumors are presented (n = 100). Fisher’s exact test. c Tspan8 immunostaining classified in 5 different immunoscores from no Tspan8 staining (score 0) to strong Tspan8 staining (score 4), according to the Breslow Index (inferior to 1 mm, between 1 and 3 mm, superior to 3 mm) and the patient status 5 years after diagnosis (dead or alive; n = 100). d Tumor number according to metastasis presence versus TSPAN8 protein expression: for patients developing or not metastases in the 5 years after diagnosis of their primary melanoma, the number of samples expressing or not Tspan8 protein as well as the percentage of Tspan8+ tumors are presented (n = 100). Fisher’s exact test. e Vital status of the patients according to Tspan8 protein expression: the number of samples expressing or not Tspan8 protein as well as the percentage of Tspan8+ tumors are presented (n = 100). Fisher’s exact test. f 5-years overall survival (n = 100). Log-rank test. g The repartition of tumors according to BRAF status and Tspan8 protein expression is presented. Fisher’s exact test
See this image and copyright information in PMC

References

    1. Ascierto PA, Marincola FM, Atkins MB. What's new in melanoma? Combination! J Transl Med. 2015;13:213. doi: 10.1186/s12967-015-0582-1. - DOI - PMC - PubMed
    1. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016. Eur J Cancer. 2016;63:201–217. doi: 10.1016/j.ejca.2016.05.005. - DOI - PubMed
    1. Agaesse G, Barbollat-Boutrand L, Sulpice E, Bhajun R, El Kharbili M, Berthier-Vergnes O, et al. A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion. Oncogene. 2017;36(4):446–457. doi: 10.1038/onc.2016.219. - DOI - PubMed
    1. El Kharbili M, Agaesse G, Barbollat-Boutrand L, Pommier RM, de la Fouchardiere A, Larue L, et al. Tspan8-beta-catenin positive feedback loop promotes melanoma invasion. Oncogene. 2019;38(20):3781–3793. doi: 10.1038/s41388-019-0691-z. - DOI - PubMed
    1. El Kharbili M, Cario M, Béchetoille N, Pain C, Boucheix C, Degoul F, et al. Tspan8 drives melanoma dermal invasion by promoting ProMMP-9 activation and basement membrane proteolysis in a keratinocyte-dependent manner. Cancers (Basel) 2020;12(5):1297. doi: 10.3390/cancers12051297. - DOI - PMC - PubMed

Publication types

MeSH terms